The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Claudin-18.2 expression & biomarker overlap in Western patients with GEA
Filip Van Herpe, MD, KU Leuven, Leuven, Belgium, discusses a retrospective single-center analysis assessing claudin-18.2 expression and its overlap with HER2, dMMR, and PDL1 in Western patients with localized and metastatic gastroesophageal adenocarcinoma (GEA). Claudin-18.2 positivity frequently co-occurred with HER2 and dMMR and was not associated with differences in survival outcomes. These findings provide insights into biomarker co-expression patterns relevant for guiding future targeted therapy strategies in Western populations. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We did a retrospective analysis in our own center of about 355 patients that were treated between 2019 and 2023. These patients were treated without zolbetuximab and we tested cross biomarkers in that study. So that means that we actually investigated the Claudin tests in comparison to all the other tests like HER2, dMMR and the PD-L1 CPS scores. Less than one, more than one, more than five and more than ten...
We did a retrospective analysis in our own center of about 355 patients that were treated between 2019 and 2023. These patients were treated without zolbetuximab and we tested cross biomarkers in that study. So that means that we actually investigated the Claudin tests in comparison to all the other tests like HER2, dMMR and the PD-L1 CPS scores. Less than one, more than one, more than five and more than ten. And what we did find was that the Claudin 18.2 expression is actually concurrently expressed throughout all biomarkers which was interesting to know that also in HER2 positive population and in PD-L1 CPS populations Claudin 18.2 gave a high expression in all these scores as well as in dMMR patients. The interesting part was that the prevalence of Claudin positivity was also equally present in our population compared to the rest of the world. And we did find also that in these patients the Claudin 18.2 was not prognostic in these patients and those were patients, mainly localized patients, around 240 patients and around 140 patients with metastatic disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consulting or Advisory Role – Merck; Merck/Pfizer
Research Funding – Amgen; Amgen; Astellas Pharma
